JonathanDMarottiMD

Pathology • Lebanon, NH

Cytopathology, Anatomic Pathology, Clinical Pathology

Assistant Professor, Pathology, Geisel School of Medicine

Join to view full profile

Are you Dr. Marotti?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 44 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
1 Medical Center Dr
# Dhmc
Lebanon, NH 03756
Phone+1 603-650-7211

Summary

Dr. Jonathan Marotti, MD is a board certified pathologist in Lebanon, New Hampshire. He is currently licensed to practice medicine in New Hampshire, Vermont, and Massachusetts. He is affiliated with Dartmouth-Hitchcock Medical Center, White River Junction Veterans Affairs Medical Center, and Cheshire Medical Center.

Education & Training

Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalFellowship, Cytopathology, 2010 - 2011
Beth Israel Deaconess Medical Center/Harvard Medical School Breast PathologyFellowship, Selective Pathology, 2009 - 2010
Beth Israel Deaconess Medical Center/Harvard Medical SchoolResidency, Pathology-Anatomic and Clinical, 2005 - 2009
Geisel School of Medicine at DartmouthClass of 2005

Certifications & Licensure

VT State Medical License 2013 - 2026
NH State Medical License 2011 - 2025
MA State Medical License 2007 - 2013
American Board of Pathology Pathology - Anatomic/Pathology - Clinical
American Board of Pathology Cytopathology

Clinical Trials

Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer. Start of enrollment: 2014 Jan 01
Completed
Not Applicable

Publications & Presentations

PubMed

Extensive epigenomic dysregulation is a hallmark of homologous recombination deficiency in triple-negative breast cancer.
Youdinghuan Chen, Lucas A Salas, Jonathan D Marotti, Nicole P Jenkins, Chao Cheng
International Journal of Cancer. 2025-03-15
Oxidative Phosphorylation is a Metabolic Vulnerability of Endocrine Therapy-Tolerant Persister Cells in ER+ Breast Cancer.
Steven Tau, Mary D Chamberlin, Huijuan Yang, Jonathan D Marotti, Patricia C Muskus
Cancer Research. 2025-01-09
Integrative co-registration of elemental imaging and histopathology for enhanced spatial multimodal analysis of tissue sections through TRACE.
Yunrui Lu, Serin Han, Aruesha Srivastava, Neha Shaik, Matthew Chan
Bioinformatics Advances. 2025-01-01

Press Mentions

Dartmouth Investigators Study Impact of Shift in Testing Guidelines for Assessing HER2 Status in Breast Cancer PatientsFebruary 12th, 2016